aMoon 2 Fund Limited Partnership 3
3 · Ayala Pharmaceuticals, Inc. · Filed May 7, 2020
Insider Transaction Report
Form 3
aMoon 2 Fund Limited Partnership
10% Owner
Holdings
- 1,313,318
Common Stock
Series A Preferred Stock
→ Common Stock (369,231 underlying)Series B Preferred Stock
→ Common Stock (508,924 underlying)
Footnotes (1)
- [F1]The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock shall be automatically converted into one (1) share of common stock upon the closing of the Issuer's initial public offering.